Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Clin Appl Thromb Hemost
2019 Jan 01;25:1076029619895323. doi: 10.1177/1076029619895323.
Show Gene links
Show Anatomy links
Principal Component Analysis on Recurrent Venous Thromboembolism.
Martins TD
,
Annichino-Bizzacchi JM
,
Romano AVC
,
Filho RM
.
???displayArticle.abstract???
The rates of recurrent venous thromboembolism (RVTE) vary widely, and its causes still need to be elucidated. Statistical multivariate methods can be used to determine disease predictors and improve current methods for risk calculation. The objective of this study was to apply principal component analysis to a set of data containing clinical records of patients with previous venous thromboembolism and extract the main factors that predict recurrent thrombosis. Records of 39 factors including blood and lipid parameters, hereditary thrombophilia, antiphospholipid syndrome, clinical data regarding previous thrombosis and treatment, and Doppler ultrasound results were collected from 235 patients. The results showed that 13 principal components were associated with RVTE and that 18 of 39 factors are the important for the analysis. These factors include red blood cell, white blood cell, hematocrit, red cell distribution width, glucose, lipids, natural anticoagulant, creatinine, age, as well as first deep vein thrombosis data (distal/proximal, d-dimer, and time of anticoagulation). The results demonstrated that simple clinical parameters easy to be collected can be used to predict rates of recurrence and to develop new clinical decision support systems to predict the rates of RVTE.
Agnelli,
Apixaban for extended treatment of venous thromboembolism.
2013, Pubmed
Agnelli,
Apixaban for extended treatment of venous thromboembolism.
2013,
Pubmed
Alt,
Blood rheology in deep venous thrombosis--relation to persistent and transient risk factors.
2002,
Pubmed
Bauersachs,
Oral rivaroxaban for symptomatic venous thromboembolism.
2010,
Pubmed
Belaj,
Changes in lipid metabolism and extension of venous thromboembolism.
2014,
Pubmed
Beyth,
Long-term outcomes of deep-vein thrombosis.
1995,
Pubmed
Bjøri,
D-dimer at venous thrombosis diagnosis is associated with risk of recurrence.
2017,
Pubmed
Boutitie,
Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials.
2011,
Pubmed
Braekkan,
Hematocrit and risk of venous thromboembolism in a general population. The Tromso study.
2010,
Pubmed
Bucciarelli,
Association between red cell distribution width and risk of venous thromboembolism.
2015,
Pubmed
Byrnes,
Red blood cells in thrombosis.
2017,
Pubmed
Carobbio,
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.
2007,
Pubmed
Chin,
A principal component analysis of postinjury viscoelastic assays: clotting factor depletion versus fibrinolysis.
2014,
Pubmed
Cosmi,
D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis.
2011,
Pubmed
DINTENFASS,
VISCOSITY AND CLOTTING OF BLOOD IN VENOUS THROMBOSIS AND CORONARY OCCLUSIONS.
1964,
Pubmed
De Stefano,
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
2008,
Pubmed
De Stefano,
The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S.
2006,
Pubmed
Deguchi,
High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men.
2005,
Pubmed
Eichinger,
High-density lipoprotein and the risk of recurrent venous thromboembolism.
2007,
Pubmed
Eichinger,
D-dimer levels and risk of recurrent venous thromboembolism.
2003,
Pubmed
Eichinger,
Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model.
2010,
Pubmed
Eischer,
Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.
2012,
Pubmed
Ensor,
Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE.
2016,
Pubmed
Esmon,
The protein C pathway.
2000,
Pubmed
Everett,
Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women.
2009,
Pubmed
Fahrni,
Assessing the risk of recurrent venous thromboembolism--a practical approach.
2015,
Pubmed
Farzamnia,
The predictive factors of recurrent deep vein thrombosis.
2011,
Pubmed
Franco,
Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis.
2017,
Pubmed
Galanaud,
Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis.
2014,
Pubmed
Gangat,
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation.
2007,
Pubmed
Grant,
Diabetes mellitus as a prothrombotic condition.
2007,
Pubmed
Guyatt,
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
2012,
Pubmed
Hansson,
Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors.
2000,
Pubmed
Heeb,
Protein S binds to and inhibits factor Xa.
1994,
Pubmed
Heit,
Predicting the risk of venous thromboembolism recurrence.
2012,
Pubmed
Heit,
Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.
2000,
Pubmed
Hull,
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.
1979,
Pubmed
Kearon,
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.
2016,
Pubmed
Kim,
High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications.
2014,
Pubmed
Kutcher,
A principal component analysis of coagulation after trauma.
2013,
Pubmed
Kyrle,
Clinical scores to predict recurrence risk of venous thromboembolism.
2012,
Pubmed
Lippi,
A review of the value of D-dimer testing for prediction of recurrent venous thromboembolism with increasing age.
2014,
Pubmed
Litvinov,
Role of red blood cells in haemostasis and thrombosis.
2017,
Pubmed
LoPresti,
Deep venous thrombosis: leukocyte rheology at baseline and after in vitro activation.
2000,
Pubmed
Marchioli,
Cardiovascular events and intensity of treatment in polycythemia vera.
2013,
Pubmed
Morelli,
Lipid levels and risk of recurrent venous thrombosis: results from the MEGA follow-up study.
2017,
Pubmed
Okin,
Principal component analysis of the T wave and prediction of cardiovascular mortality in American Indians: the Strong Heart Study.
2002,
Pubmed
Pabinger,
Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors.
1996,
Pubmed
Palareti,
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study.
2014,
Pubmed
Palareti,
Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.
2002,
Pubmed
Palareti,
Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.
2003,
Pubmed
Rezende,
Hematologic variables and venous thrombosis: red cell distribution width and blood monocyte count are associated with an increased risk.
2014,
Pubmed
Rodger,
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy.
2008,
Pubmed
Rosendaal,
Genetics of venous thrombosis.
2009,
Pubmed
Saraiva,
Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response.
2015,
Pubmed
Schulman,
The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
1997,
Pubmed
Shlipak,
Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency.
2003,
Pubmed
Silverstein,
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.
1998,
Pubmed
Thorpe,
A comparison of the dietary patterns derived by principal component analysis and cluster analysis in older Australians.
2016,
Pubmed
Tosetto,
Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH).
2012,
Pubmed
Tsai,
Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology.
2002,
Pubmed
Vavougios,
Phenotypes of comorbidity in OSAS patients: combining categorical principal component analysis with cluster analysis.
2016,
Pubmed
Vayá,
Hemorheological parameters as independent predictors of venous thromboembolism.
2013,
Pubmed
Verhovsek,
Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism.
2008,
Pubmed
WELLS,
Influence of flow properties of blood upon viscosity-hematocrit relationships.
1962,
Pubmed
White,
Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism.
1998,
Pubmed
Xu,
A multiscale model of venous thrombus formation with surface-mediated control of blood coagulation cascade.
2010,
Pubmed
Yu,
A local increase in red blood cell aggregation can trigger deep vein thrombosis: evidence based on quantitative cellular ultrasound imaging.
2011,
Pubmed
van der Hulle,
Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism.
2015,
Pubmed